Drug Trial Radar · NCT04086264
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
218
Actual
Start
Nov 6, 2019
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in participants with relapsed and frontline CD123-positive AML.
Conditions
- Acute Myeloid Leukemia
Interventions
AzacitidineDrug
Commercially available formulation given subcutaneously (SC) or intravenous (IV)
IMGN632Drug
Study formulation given intravenously (IV)
VenetoclaxDrug
Commercially available formulation administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: approximately 3 years
- Preliminary antileukemia activityTime frame: approximately 20 months
- Minimal Residual Disease LevelsTime frame: approximately 18 months
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center /ID# 269273
Duarte, California
University Of California Irvine Medical Center /ID# 269275
Orange, California
Moffitt Cancer Center /ID# 269269
Tampa, Florida
Northwestern University- Robert H. Lurie Comprehensive Cancer Center /ID# 269642
Chicago, Illinois
Dana-Farber Cancer Institute /ID# 269267
Boston, Massachusetts
University of Michigan /ID# 269079
Ann Arbor, Michigan
Mayo Clinic Hospital Rochester /ID# 269643
Rochester, Minnesota
Roswell Park Cancer Institute /ID# 269266
Buffalo, New York
New York Presbyterian Hospital Weill Cornell Medical Center /ID# 269271
New York, New York
Duke University Health System /ID# 269268
Durham, North Carolina
Cleveland Clinic - Cleveland /ID# 269272
Cleveland, Ohio
MD Anderson Houston /ID# 269265
Houston, Texas
Fred Hutchinson Cancer Research Center /ID# 269270
Seattle, Washington
Centre Hospitalier de Versailles André Mignot /ID# 269287
Le Chesnay, France
Institut Paoli-Calmettes /ID# 269080
Marseille, Bouches-du-Rhone, France
IUCT Oncopole /ID# 269284
Toulouse, Occitanie, France
Hôpital Saint-Louis /ID# 269282
Paris, Paris, France
Centre Antoine-Lacassagne /ID# 269285
Nice, Provence-Alpes-Côte d'Azur Region, France
Hospices Civils de Lyon - Centre Hospitalier Lyon-Sud /ID# 269286
Pierre-Bénite, Rhone, France
Universitaetsklinikum Ulm /ID# 269686
Ulm, Baden-Wurttemberg, Germany
Universitaetsklinikum Muenster /ID# 269688
Münster, North Rhine-Westphalia, Germany
Universitaetsklinikum Leipzig /ID# 269682
Leipzig, Saxony, Germany
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 269281
Bologna, Bologna, Italy
Istituto Europeo Di Oncologia /ID# 269646
Milan, Milano, Italy
Azienda Ospedaliero Universitaria Maggiore Della Carità /ID# 269280
Novara, Novara, Italy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 269279
Meldola, Reggio Emilia, Italy
Hospital MD Anderson Cancer Center Madrid /ID# 269641
Madrid, Madrid, Spain
Hospital Universitario y Politecnico La Fe /ID# 269278
Valencia, Valencia, Spain
Oxford University Hospital NHS Trust /ID# 269647
Oxford, Oxfordshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.